Background: Puberty is thought to be commonly affected in adolescents with inflammatory bowel disease (IBD). Aims: To determine the impact of Crohn’s disease (CD) and ulcerative colitis (UC) on the pubertal growth spurt. Methods: Retrospective study of 30 boys with CD (CD-M), 11 girls with CD (CD-F), 14 boys with UC (UC-M) and 12 girls with UC (UC-F). Pubertal growth was assessed by calculating peak height velocity SDS (PHV SDS), height SDS at diagnosis (HtDiag) and height SDS at PHV (HtPHV) and age at PHV (AgePHV). Systemic markers of disease activity were also collected. Results: Altered parameters of pubertal growth were observed in the CD groups compared to the normal population: in the CD-M group, median HtDiag was –0.56 (p = 0.001) and median AgePHV was 14.45 years (p = 0.004), and in the CD-F group, median HtDiag was –1.14 (p = 0.007) and HtPHV was –0.79 (p = 0.039). Individually, 8/30 CD-M cases had one or more parameter affected: 2 boys had HtDiag <–2, 3 boys had HtPHV <–2, 2 boys had an AgePHV >2 years above population mean, and 2 boys had a PHV SDS <–2. In the whole group, AgePHV showed an association with erythrocyte sedimentation rate (r = 0.4; p = 0.005) and an inverse association with BMI (r = 0.4; p = 0.001). Conclusion: Disorders of pubertal growth are more likely to occur in CD and, particularly, in boys.

1.
Ballinger AB, Savage MO, Sanderson IR: Delayed puberty associated with inflammatory bowel disease. Pediatr Res 2003;53:205–210.
2.
McCaffery TD, Nasr K, Lawrence AM, Kirsner JB: Severe growth retardation in children with inflammatory bowel disease. Pediatrics 1970;45:386–393.
3.
Azooz OG, Farthing MJ, Savage MO, Ballinger AB: Delayed puberty and response to testosterone in a rat model of colitis. Am J Physiol Regul Integr Comp Physiol 2001;281:R1483–R1491.
4.
Khalkhali-Ellis Z, Moore TL, Hendrix MJ: Reduced levels of testosterone and dehydroepiandrosterone sulphate in the serum and synovial fluid of juvenile rheumatoid arthritis patients correlates with disease severity. Clin Exp Rheumatol 1998;16:753–756.
5.
Morales V, Santana P, Diaz R, Tabraue C, Gallardo G, Lopez BF, Hernandez I, Fanjul LF, Ruiz de Galarreta CM: Intratesticular delivery of tumor necrosis factor-alpha and ceramide directly abrogates steroidogenic acute regulatory protein expression and Leydig cell steroidogenesis in adult rats. Endocrinology 2003;144:4763–4772.
6.
Ko S, Shi L, Kim S, Song CS, Chatterjee B: Interplay of nuclear factor-kappaB and B-myb in the negative regulation of androgen receptor expression by tumor necrosis factor alpha. Mol Endocrinol 2008;22:273–286.
7.
Brain CE, Savage MO: Growth and puberty in chronic inflammatory bowel disease. Baillieres Clin Gastroenterol 1994;8:83–100.
8.
Pfefferkorn M, Burke G, Griffiths A, Markowitz J, Rosh J, Mack D, Otley A, Kugathasan S, Evans J, Bousvaros A, Moyer MS, Wyllie R, Oliva-Hemker M, Carvalho R, Crandall W, Keljo D, Walters TD, LeLeiko N, Hyams J: Growth abnormalities persist in newly diagnosed children with Crohn’s disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr 2009;48:168–174.
9.
Ahmed SF, Wong JS, McGrogan P: Improving growth in children with inflammatory bowel disease. Horm Res 2007;68(suppl 5): 117–121.
10.
Malik S, Wong SC, Bishop J, Hassan K, McGrogan P, Ahmed SF, Russell RK: Improvement in growth of children with Crohn disease following anti-TNF-alpha therapy can be independent of pubertal progress and glucocorticoid reduction. J Pediatr Gastroenterol Nutr 2011;52:31–37.
11.
Sawczenko A, Ballinger AB, Croft NM, Sanderson IR, Savage MO: Adult height in patients with early onset of Crohn’s disease. Gut 2003;52:454–455.
12.
Kelly BP, Paterson WF, Donaldson MD: Final height outcome and value of height prediction in boys with constitutional delay in growth and adolescence treated with intramuscular testosterone 125 mg per month for 3 months. Clin Endocrinol (Oxf) 2003;58:267–272.
13.
Perry RJ, Farquharson C, Ahmed SF: The role of sex steroids in controlling pubertal growth. Clin Endocrinol (Oxf) 2008;68:4–15.
14.
Karaolis-Danckert N, Buyken AE, Sonntag A, Kroke A: Birth and early life influences on the timing of puberty onset: results from the DONALD (DOrtmund Nutritional and Anthropometric Longitudinally Designed) Study. Am J Clin Nutr 2009;90:1559–1565.
15.
Aksglaede L, Juul A, Olsen LW, Sorensen TI: Age at puberty and the emerging obesity epidemic. PLoS One 2009;4:e8450.
16.
IBD Working Group of the European Society for Paediatric Gastroenterology Hepatology and Nutrition: Inflammatory bowel disease in children and adolescents: recommendations for diagnosis – the Porto criteria. J Pediatr Gastroenterol Nutr 2005;41:1–7.
17.
Lennard-Jones JE: Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989;170:2–6.
18.
Freeman JV, Cole TJ, Chinn S, Jones PR, White EM, Preece MA: Cross sectional stature and weight reference curves for the UK, 1990. Arch Dis Child 1995;73:17.
19.
Gasser T, Sheehy A, Molinari L, Largo RH: Sex dimorphism in growth. Ann Hum Biol 2000;27:187–197.
20.
Tanner JM, Goldstein H, Whitehouse RH: Standards for children’s height at ages 2–9 years allowing for heights of parents. Arch Dis Child 1970;45:755–762.
21.
Zachmann M, Prader A, Sobel EH, Crigler JF Jr, Ritzen EM, Atares M, Ferrandez A: Pubertal growth in patients with androgen insensitivity: indirect evidence for the importance of estrogens in pubertal growth of girls. J Pediatr 1986;108:694–697.
22.
Griffiths AM, Nguyen P, Smith C, MacMillan JH, Sherman PM: Growth and clinical course of children with Crohn’s disease. Gut 1993;34:939–943.
23.
Gupta N, Lustig RH, Kohn MA, McCracken M, Vittinghoff E: Sex differences in statural growth impairment in Crohn’s disease: role of IGF-1. Inflamm Bowel Dis 2011, Epub ahead of print.
24.
Wong SC, Smyth A, McNeill E, Galloway PJ, Hassan K, McGrogan P, Ahmed SF: The growth hormone insulin-like growth factor 1 axis in children and adolescents with inflammatory bowel disease and growth retardation. Clin Endocrinol (Oxf) 2010;73:220–228.
25.
Martinez AS, Domene HM, Ropelato MG, Jasper HG, Pennisi PA, Escobar ME, Heinrich JJ: Estrogen priming effect on growth hormone (GH) provocative test: a useful tool for the diagnosis of GH deficiency. J Clin Endocrinol Metab 2000;85:4168–4172.
26.
Jansson JO, Ekberg S, Isaksson OG, Eden S: Influence of gonadal steroids on age- and sex-related secretory patterns of growth hormone in the rat. Endocrinology 1984;114:1287–1294.
27.
Krieg RJ Jr, Veldhuis JD, Thornhill BA, Chevalier RL, Gil G: Growth hormone (GH) secretion, GH-dependent gene expression, and sexually dimorphic body growth in young rats with chronic renal failure. Endocrine 2008;33:323–330.
28.
Elmantaser M, Stewart G, Young D, Duncan R, Gibson B, Ahmed SF: Skeletal morbidity in children receiving chemotherapy for acute lymphoblastic leukaemia. Arch Dis Child 2010;95:805–809.
29.
van Diemen-Steenvoorde R, Donckerwolcke RA, Brackel H, Wolff ED, de Jong MC: Growth and sexual maturation in children after kidney transplantation. J Pediatr 1987;110:351–356.
30.
Cooper R, Blell M, Hardy R, Black S, Pollard TM, Wadsworth ME, Pearce MS, Kuh D: Validity of age at menarche self-reported in adulthood. J Epidemiol Community Health 2006;60:993–997.
31.
Buyken AE, Karaolis-Danckert N, Remer T: Association of prepubertal body composition in healthy girls and boys with the timing of early and late pubertal markers. Am J Clin Nutr 2009;89:221–230.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.